https://www.pharmaradar360.com/article/5479295b1e717a4aPharmaRadar360en2026-04-23T11:08:54.000ZNeues „WHO-Kollaborationszentrum für neuartige Diagnostika für Infektionskrankheiten“ am Universitätsklinikum Heidelberghttps://www.pharmaradar360.com/article/b76671dec6688542PharmaRadar360en2026-04-23T11:00:51.000ZGravity Rail raises $2.75M from Redesign Health for AI patient communicationhttps://www.pharmaradar360.com/article/c087b6093085004ePharmaRadar360en2026-04-23T10:47:53.000ZRoche says its investigational breast cancer pill could outsell Herceptinhttps://www.pharmaradar360.com/article/25122a5d2ad4a8dePharmaRadar360en2026-04-23T10:13:06.000ZDierproeven: verminderen, verfijnen, vervangenhttps://www.pharmaradar360.com/article/096f9ed25b858937PharmaRadar360en2026-04-23T10:01:45.000ZBesonderes Trainingsangebot eingeweihthttps://www.pharmaradar360.com/article/2842acc8a945f395PharmaRadar360en2026-04-23T10:01:39.000ZClass 3 Medicines Recall: Omega Pharma Ltd, Napralief 250mg Gastro-Resistant Tablets, EL(26)A/21https://www.pharmaradar360.com/article/c2b5975e86970dc2PharmaRadar360en2026-04-23T10:00:00.000ZHow is the Role of Non-Viral Cell Engineering Technology Growing in Advanced Therapies?https://www.pharmaradar360.com/article/d5f9b9f39a87bcf4PharmaRadar360en2026-04-23T09:57:56.000ZCalluna concludes patient enrolment in Phase II trial for IPFhttps://www.pharmaradar360.com/article/5e14a8ae324e2d8ePharmaRadar360en2026-04-23T09:57:52.000ZSanofi receives FDA approval for Tzield in paediatric diabeteshttps://www.pharmaradar360.com/article/d043dbda34dd83afPharmaRadar360en2026-04-23T09:55:24.000ZFor the first time, scientists pinpoint the brain cells behind depressionhttps://www.pharmaradar360.com/article/8a7994ee12f4ed57PharmaRadar360en2026-04-23T09:43:53.000ZLa AEMPS informa del cese de comercialización, retirada del mercado y recuperación de los cosméticos Blonde Henna y Oil Balance, de la marca Real Earthhttps://www.pharmaradar360.com/article/24a6fe004c07f460PharmaRadar360en2026-04-23T09:38:03.000ZLaunch of the Graduate School Cardiovascular and Blood Sciences (CVBS): An Integrated Approach to Circulatory Healthhttps://www.pharmaradar360.com/article/c293caf0ceafd198PharmaRadar360en2026-04-23T09:36:58.000ZAbbVie opts for North Carolina to house $1.4bn manufacturing sitehttps://www.pharmaradar360.com/article/5b75f63ef98820a0PharmaRadar360en2026-04-23T09:20:45.000ZResearch group contributes to the territorial future of the EUhttps://www.pharmaradar360.com/article/94a90960849b8acdPharmaRadar360en2026-04-23T09:19:55.000ZConsumers gloomy, but economy holds steady: ‘No reason for panic’https://www.pharmaradar360.com/article/f573d6b7654610d8PharmaRadar360en2026-04-23T09:00:47.000ZSanofi defends Garijo appointment, says it is 'fully committed' to immunologyhttps://www.pharmaradar360.com/article/790bed353c85c874PharmaRadar360en2026-04-23T09:00:00.000ZLos beneficios de la actividad física pueden superar los riesgos en niños con ciertas afecciones cardíacashttps://www.pharmaradar360.com/article/4839167f4b38916cPharmaRadar360en2026-04-23T09:00:00.000ZBenefits of physical activity may outweigh risks for children with some heart conditionshttps://www.pharmaradar360.com/article/b3145601ee35a4b3PharmaRadar360en2026-04-23T08:58:14.000ZUnelmien katu on kaikkien katu: puhujien pohdintoja kirjajulkaisutilaisuudessa 13.4.https://www.pharmaradar360.com/article/0315a8cd0202048fPharmaRadar360en2026-04-23T08:49:44.000ZUniklinikum Dresden stärkt den Bereich Transformationhttps://www.pharmaradar360.com/article/02888e904fb96026PharmaRadar360en2026-04-23T08:34:51.000ZAiforia closes a deal with a private diagnostic laboratory in Italyhttps://www.pharmaradar360.com/article/5abacd5f68071e0aPharmaRadar360en2026-04-23T08:34:32.000ZIssue of Identity project - Online course piloting in April 2026https://www.pharmaradar360.com/article/97022f3deac75fa4PharmaRadar360en2026-04-23T08:29:59.000ZOperational Lessons from Global Nephrology Trialshttps://www.pharmaradar360.com/article/6b862f02c2f09886PharmaRadar360en2026-04-23T08:29:59.000ZOperational Lessons from Global Nephrology Trialshttps://www.pharmaradar360.com/article/85c52e53cba9abdaPharmaRadar360en2026-04-23T08:25:38.000ZUK cancer cases exceed 400,000 a year for the first timehttps://www.pharmaradar360.com/article/b71a76f89f765c54PharmaRadar360en2026-04-23T08:15:52.000ZESR sees huge engagement thanks to ESOR Special Focus Courses on Tuberculosis and Cardiac MRhttps://www.pharmaradar360.com/article/05a8dd5077afe579PharmaRadar360en2026-04-23T08:15:00.000Z“Mamma, mi leggi una storia ad alta voce?”. Tutti i motivi per rispondere “sì!”https://www.pharmaradar360.com/article/491d6cf18205b576PharmaRadar360en2026-04-23T08:10:16.000ZOvercoming challenges in a pediatric infectious disease trialhttps://www.pharmaradar360.com/article/de8ebcfda1703237PharmaRadar360en2026-04-23T08:05:29.000Z17.4. Seminar Racial biology in the Nordics: Still an open field in polarized times?https://www.pharmaradar360.com/article/d2584eef9a4d12caPharmaRadar360en2026-04-23T07:52:20.000ZVan cijfers naar keuzes: hoe houden we de innovatiespiraal draaiende?https://www.pharmaradar360.com/article/745dd98ca5df5490PharmaRadar360en2026-04-23T07:52:00.000ZUniversityCentre of Orthopedics, Traumatology & Plastic Surgeryhttps://www.pharmaradar360.com/article/87d2eeef979ed13dPharmaRadar360en2026-04-23T07:49:51.000ZModeX starts dosing in MDX2003 trial for B-cell lymphomahttps://www.pharmaradar360.com/article/c86a07ed0b2a65ddPharmaRadar360en2026-04-23T07:49:27.000ZMSD teams up with Google Cloud on agentic AI transformationhttps://www.pharmaradar360.com/article/4a4f342198af597aPharmaRadar360en2026-04-23T07:38:59.000ZKontakthttps://www.pharmaradar360.com/article/6b86f64e99d8479bPharmaRadar360en2026-04-23T07:38:55.000ZNew case law could put radiologists on hook for imaging-order appropriatenesshttps://www.pharmaradar360.com/article/a71aded0625a123ePharmaRadar360en2026-04-23T07:31:13.000ZInterventional radiologists launch new chain of standalone outpatient IR centershttps://www.pharmaradar360.com/article/80c0cfc5e1a8bd69PharmaRadar360en2026-04-23T07:21:01.000ZKnoten im Halshttps://www.pharmaradar360.com/article/adf9069bfe0c5644PharmaRadar360en2026-04-23T07:17:49.000Z4S (κάψουλες) (SIBUTRAMINE, PHENOLPHTALEIN)https://www.pharmaradar360.com/article/a1f32b1cca0d03b9PharmaRadar360en2026-04-23T07:13:17.000ZBoletín sobre Seguridad de Medicamentos de Uso Humano. Febrero de 2026https://www.pharmaradar360.com/article/db61010f53418ccePharmaRadar360en2026-04-23T07:12:57.000ZBABA BERATAN HERBAL MIXTURE, GENTLE DMP DOMIPA HERBAL MIXTURE, MANISA HERBAL MIXTURE, BITKISEL KARISIMLI EPIMEDYUMLU MACUN, LA PEPA NEGRA, ROYAL HONEYhttps://www.pharmaradar360.com/article/7b47458f77119b03PharmaRadar360en2026-04-23T07:12:29.000ZRadiologists No. 1 among physician specialists with $5M or more in net worth: Medscapehttps://www.pharmaradar360.com/article/2069b29340cb25b1PharmaRadar360en2026-04-23T07:11:50.000ZDigitale Fortschrittshubs präsentieren sich auf der DMEAhttps://www.pharmaradar360.com/article/7a4daf1c60db9dfcPharmaRadar360en2026-04-23T07:10:00.000ZStudent-teacher Paul teaches gifted children: 'Here, they’re really allowed to move at a faster pace and, above all, be curious'https://www.pharmaradar360.com/article/3f08600a212677fcPharmaRadar360en2026-04-23T07:08:05.000ZAMME Sem­inar 07.05.26: ‘Cuneiform Texts and Scribal Adaptation’https://www.pharmaradar360.com/article/a7b745cb7dcf24cbPharmaRadar360en2026-04-23T07:05:07.000ZAMME Seminar 07.05.26: ‘Cuneiform Texts and Scribal Adaptation’https://www.pharmaradar360.com/article/1100c635dc15bac1PharmaRadar360en2026-04-23T07:00:00.000ZMake a gift by noon today For the Greater Goodhttps://www.pharmaradar360.com/article/08c955ebd047e9e9PharmaRadar360en2026-04-23T07:00:00.000ZWereldvaccinatieweek 2026: ouderen willen zich laten vaccineren, maar missen een duidelijk vaccinatiebeleidhttps://www.pharmaradar360.com/article/b0c96cb56813b41bPharmaRadar360en2026-04-23T06:58:19.000ZΑπαγόρευση διάθεσης και διακίνησης των συμπληρωμάτων διατροφής YAVA LABS – FAT BURNER BLUEBERRY και YAVA LABS – FAT BURNER COLAhttps://www.pharmaradar360.com/article/2b1cd02dd4515c33PharmaRadar360en2026-04-23T06:58:00.000ZCharity Evans, MD, named inaugural Wright Professorhttps://www.pharmaradar360.com/article/69407afce1255301PharmaRadar360en2026-04-23T06:56:00.000ZGraduate Medical Education Research Symposium set for May 12https://www.pharmaradar360.com/article/de78b672471b02faPharmaRadar360en2026-04-23T06:54:00.000ZSign up for UNMC’s summer intramural leagueshttps://www.pharmaradar360.com/article/e47bff72bbe5326bPharmaRadar360en2026-04-23T06:52:00.000ZLane shift begins April 27 along 42nd Streethttps://www.pharmaradar360.com/article/9e1631e988a0af37PharmaRadar360en2026-04-23T06:48:02.000ZChanges to pathology results from Sunday, 3 Mayhttps://www.pharmaradar360.com/article/69188ab6cb4f2340PharmaRadar360en2026-04-23T06:45:11.000ZSimple “gut reset” may stop weight gain after Ozempic or Wegovyhttps://www.pharmaradar360.com/article/f19bd573b6f725a5PharmaRadar360en2026-04-23T06:30:00.000ZAnna Baiges Aznar receives the AEEH Rising Star grant for her scientific contributionshttps://www.pharmaradar360.com/article/b5b1228ad8a1ecb9PharmaRadar360en2026-04-23T06:19:18.000ZNew funding opportunities pave the way for better diagnostics and treatment as well as for engineering efficient biosolutions and replacing critical and scarce resourceshttps://www.pharmaradar360.com/article/6ff13327677e1e34PharmaRadar360en2026-04-23T06:00:00.000Z#PASSAPAROLA [26.05] Cure palliative risorse per la polishttps://www.pharmaradar360.com/article/4e0e6f65b9a29843PharmaRadar360en2026-04-23T05:28:00.000ZDeerfield trots into pharma sales software space with CRM-enhancing toolhttps://www.pharmaradar360.com/article/d07217edc6dfc001PharmaRadar360en2026-04-23T05:20:00.000ZFrom debt to ‘acceptable’ prices: Roche CEO lists 3 reasons for sitting out Big Pharma M&A spreehttps://www.pharmaradar360.com/article/de6fa444c402f62bPharmaRadar360en2026-04-23T05:16:00.000Z#PASSAPAROLA. [11.05] Quinta giornata nazionale per la promozione del neurosviluppo: scopri le iniziative del Policlinico di Milano!https://www.pharmaradar360.com/article/a6d7fdb12a86a3e5PharmaRadar360en2026-04-23T05:12:42.000Z[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franchttps://www.pharmaradar360.com/article/5a06b180bea05ca7PharmaRadar360en2026-04-23T05:10:52.000ZStrong Q1 2026 sales growth, marking a solid start to the yearhttps://www.pharmaradar360.com/article/32de5cb883ad04eePharmaRadar360en2026-04-23T05:07:33.000Z【開催のご案内】KSMO 2026（韓国・Korean Society of Medical Oncology ）Call for Abstracts: Deadline – May 8 (Fri), 2026 (KST)https://www.pharmaradar360.com/article/5f8852d799d4f5c2PharmaRadar360en2026-04-23T05:01:21.000ZfMRI-Based Mega-Study of Psychedelics Reveals Patterns of Brain Signaling Reorganizationhttps://www.pharmaradar360.com/article/29f1f880fc31e41dPharmaRadar360en2026-04-23T05:00:00.000Z#PASSAPAROLA. [09.05] Esofagite Eosinofila: tra cibo, cure e qualità di vita. Incontro Medici-Pazientihttps://www.pharmaradar360.com/article/b1dfd5427a0ce191PharmaRadar360en2026-04-23T05:00:00.000Zエフ・ホフマン・ラ・ロシュの2026年第1四半期の販売実績についてhttps://www.pharmaradar360.com/article/f8d491c10782d4f1PharmaRadar360en2026-04-23T05:00:00.000ZF. Hoffmann-La Roche Announces First Quarter Sales 2026https://www.pharmaradar360.com/article/c82f97c9d8ff3a07PharmaRadar360en2026-04-23T04:42:24.000Z【開催のご案内】Upcoming Deadline: ASCO Breakthrough Early Registration Ends May 20https://www.pharmaradar360.com/article/16ff636d11792b75PharmaRadar360en2026-04-23T04:08:00.000ZSanofi CFO defends Hudson’s Dupixent legacy, but accepts ‘number of setbacks’ in R&Dhttps://www.pharmaradar360.com/article/054b1d81a6079340PharmaRadar360en2026-04-23T04:05:00.000ZMerck’s new AI commercial strategy ‘reimagining engagement with HCPs’https://www.pharmaradar360.com/article/feb51fd3df361c17PharmaRadar360en2026-04-23T03:25:13.000ZScientists create plastic that destroys viruses on contacthttps://www.pharmaradar360.com/article/0074e023a10ddfc8PharmaRadar360en2026-04-23T03:23:00.000ZCity of Arlington expands smoke-free ordinance, becoming a model for clean indoor air in Texashttps://www.pharmaradar360.com/article/8dec0c52b1fe5395PharmaRadar360en2026-04-23T02:00:00.000ZAgenda for May 2026 Immunisation Advisory Committee (IAC) meetinghttps://www.pharmaradar360.com/article/e0052adead419492PharmaRadar360en2026-04-23T01:39:55.000ZNew study offers insight into the type of AI radiologists preferhttps://www.pharmaradar360.com/article/268449918a370baaPharmaRadar360en2026-04-23T01:32:36.000ZCSafe Advanced Parcel Data Sheethttps://www.pharmaradar360.com/article/d3322d8e7d4b3949PharmaRadar360en2026-04-23T01:06:41.000ZThis simple fatty acid could restore failing visionhttps://www.pharmaradar360.com/article/b31ecc7f494e4419PharmaRadar360en2026-04-23T00:58:57.000Z¡Súmate a la Fiesta de los Libros!: Revisa las iniciativas y actividades en la UChttps://www.pharmaradar360.com/article/02dcc0ca266dae85PharmaRadar360en2026-04-23T00:38:42.000ZWhat Does DOJ’s New Corporate Enforcement Policy Mean for the FDA- and DEA-Regulated Industry?https://www.pharmaradar360.com/article/436a52a9582ca6f5PharmaRadar360en2026-04-23T00:30:34.000ZWuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeuticshttps://www.pharmaradar360.com/article/eaa759fe8dc3e3ddPharmaRadar360en2026-04-23T00:28:00.000ZCentral Arkansas Heart Walk unites community to save lives and honor survivorshttps://www.pharmaradar360.com/article/f45d42666c464e68PharmaRadar360en2026-04-23T00:26:25.000ZExpertos analizan cómo la desinformación, la violencia y la polarización desafían a la democraciahttps://www.pharmaradar360.com/article/c084970771c3eab1PharmaRadar360en2026-04-23T00:00:00.000ZRecor Medical's Paradise Ultrasound Renal Denervation System Honored with TAG Award for Cardiovascular Therapeutic Innovation (Link to Recor website)https://www.pharmaradar360.com/article/d69d107f370181e6PharmaRadar360en2026-04-23T00:00:00.000ZNew payloads drive next-gen antibody–drug conjugateshttps://www.pharmaradar360.com/article/7df060ba33de774ePharmaRadar360en2026-04-23T00:00:00.000ZBOLD fMRI reflects both vascular and metabolic signalshttps://www.pharmaradar360.com/article/4372713bc58648b6PharmaRadar360en2026-04-23T00:00:00.000ZEarly dopamine disruption in the entorhinal cortex of a knock-in model of Alzheimer’s diseasehttps://www.pharmaradar360.com/article/1ebf0b271bc43c02PharmaRadar360en2026-04-23T00:00:00.000ZHow to meaningfully evaluate AI in clinical medicinehttps://www.pharmaradar360.com/article/c08d34e1f32e686bPharmaRadar360en2026-04-23T00:00:00.000ZIntestinal metaplasia is the only precursor to esophageal adenocarcinomahttps://www.pharmaradar360.com/article/21aa96a6575c47ffPharmaRadar360en2026-04-23T00:00:00.000ZAfrica’s moment for health securityhttps://www.pharmaradar360.com/article/d92194d091758c61PharmaRadar360en2026-04-23T00:00:00.000ZHigh-fidelity intravital imaging of biological dynamics with latent-space-enhanced digital adaptive opticshttps://www.pharmaradar360.com/article/d80146cb5b3be5b1PharmaRadar360en2026-04-23T00:00:00.000ZGenome editing of phylogenetically distinct bacteria using cross-species retron-mediated recombineeringhttps://www.pharmaradar360.com/article/e9f894428bcc7b61PharmaRadar360en2026-04-23T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/da03f9fbacdcb7b0PharmaRadar360en2026-04-23T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/a746fd0ece61f304PharmaRadar360en2026-04-23T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/6d4e5e0cfab91670PharmaRadar360en2026-04-23T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/323d38f7b5759d7dPharmaRadar360en2026-04-23T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/9917136ea180f184PharmaRadar360en2026-04-23T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/6db6497e8a0b299cPharmaRadar360en2026-04-23T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/3aa90d4c06611fb7PharmaRadar360en2026-04-23T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/5044c9b6044f201ePharmaRadar360en2026-04-23T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/96c61092ea20e381PharmaRadar360en2026-04-23T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/d0a5bc383d325fc0PharmaRadar360en2026-04-23T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/27eedf1e64530b3dPharmaRadar360en2026-04-23T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/14d558ddc7d97969PharmaRadar360en2026-04-23T00:00:00.000Z6203https://www.pharmaradar360.com/article/6f3b786feacd2b9bPharmaRadar360en2026-04-23T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/0e4fc9a93fe9635cPharmaRadar360en2026-04-23T00:00:00.000ZTryggare uppväxt gav bättre liv – även för nästa generationhttps://www.pharmaradar360.com/article/c08355903fc8f980PharmaRadar360en2026-04-23T00:00:00.000ZARC:s verksamhetsrapport 2023–2025 finns nu i digital formhttps://www.pharmaradar360.com/article/693ce280b0c7aa0fPharmaRadar360en2026-04-22T23:41:09.000ZCare by name, but not by naturehttps://www.pharmaradar360.com/article/f1e6a266491201cdPharmaRadar360en2026-04-22T22:47:37.000ZOrganigrama, autoridades y personalhttps://www.pharmaradar360.com/article/eb65e21afe847395PharmaRadar360en2026-04-22T22:43:00.000ZLocal banking professional and longtime advocate Martha S. Porter to lead 2026 New Mexico Heart Walk and 5K Runhttps://www.pharmaradar360.com/article/8f599c588093538bPharmaRadar360en2026-04-22T22:14:34.000ZInterventional radiology procedure offers relief from painful blood-clot side effecthttps://www.pharmaradar360.com/article/267f7ba3e852652ePharmaRadar360en2026-04-22T21:44:00.000ZCentral Arkansas’ Sam Kamran named 2026 Woman of Impact winner as local leaders join national fight against women’s No. 1 killerhttps://www.pharmaradar360.com/article/565c07afcc336a2aPharmaRadar360en2026-04-22T21:28:11.000ZFDA clears Philips' CT platform that streamlines and coordinates workflowshttps://www.pharmaradar360.com/article/165a802fca7776f3PharmaRadar360en2026-04-22T21:23:33.000ZEcopipam Significantly Reduces Risk of Relapse in Pediatric, Overall Populations With Tourette Syndromehttps://www.pharmaradar360.com/article/657b55f0f827bca4PharmaRadar360en2026-04-22T21:05:04.000ZShoulder Innovations to Report First Quarter 2026 Financial Results on May 13, 2026https://www.pharmaradar360.com/article/840f71460624fadaPharmaRadar360en2026-04-22T20:46:41.000ZNuevo estudio de grabación en la Unidad º9https://www.pharmaradar360.com/article/eb9198c6f94f024ePharmaRadar360en2026-04-22T20:40:05.000ZMonthly Biologics News & Articles | WuXi Biologics | Aprilhttps://www.pharmaradar360.com/article/076c0cd6d99fda00PharmaRadar360en2026-04-22T20:39:05.000ZInformación Electrónica de Prescripción (ePI): Acelerando la Transformación Digital de los Sistemas de Salud en América Latinahttps://www.pharmaradar360.com/article/57f71c2af5534da6PharmaRadar360en2026-04-22T20:15:00.000ZMedpace Holdings, Inc. Reports First Quarter 2026 Resultshttps://www.pharmaradar360.com/article/5686ccdc61afcd05PharmaRadar360en2026-04-22T20:07:25.000ZInauguración del Estudio de Grabación “Dardo Cabo” en la Unidad Nº9https://www.pharmaradar360.com/article/090b60c9d35c7737PharmaRadar360en2026-04-22T20:00:38.000ZOpenAI's head of health lays out the AI giant’s healthcare ambitionshttps://www.pharmaradar360.com/article/5539e67883714b43PharmaRadar360en2026-04-22T20:00:00.000ZMIT affiliates elected to the American Academy of Arts and Sciences for 2026https://www.pharmaradar360.com/article/9c7a7180228f7585PharmaRadar360en2026-04-22T19:56:02.000ZKFF Tracker: America First MOU Bilateral Global Health Agreementshttps://www.pharmaradar360.com/article/b88d1b90c646ddd8PharmaRadar360en2026-04-22T19:55:29.000ZWhat to Know About the BALANCE Model for GLP-1s in Medicare and Medicaidhttps://www.pharmaradar360.com/article/e75342cf5a9cc4b6PharmaRadar360en2026-04-22T19:53:13.000ZNot All Intravenous Irons Are Created Equal: Considerations for Rate of Iron Release, Efficacy, Safety, and Tolerabilityhttps://www.pharmaradar360.com/article/67e80fb379bdd516PharmaRadar360en2026-04-22T19:35:29.000ZLa UNLP presentó su nueva sopa crema de hongos deshidratada: ciencia y nutrición con alcance socialhttps://www.pharmaradar360.com/article/d8eac76819e7bbf6PharmaRadar360en2026-04-22T19:34:55.000ZHistórico: Tauber fue proclamado presidente de la UNLP con el 100 % de los votos de la Asamblea Universitariahttps://www.pharmaradar360.com/article/10f10f363004cf78PharmaRadar360en2026-04-22T19:34:01.000ZLa UNLP presentó el Ciclo de Formación en Memoria y Acervos 2026https://www.pharmaradar360.com/article/f99d7104b036debePharmaRadar360en2026-04-22T19:33:36.000ZSíndrome metabólico y metformina: impacto simultáneo en huesos y arteriashttps://www.pharmaradar360.com/article/0222f178b0a562b9PharmaRadar360en2026-04-22T19:33:11.000ZFernando Tauber, Doctor Honoris Causa de la Universidad Nacional de La Pampahttps://www.pharmaradar360.com/article/e0bb61b1aa802839PharmaRadar360en2026-04-22T19:30:22.000ZTauber recorrió el avance de las obras del Centro de Atención Primaria en Salud de la UNLP, en Berissohttps://www.pharmaradar360.com/article/b17dbd911f61fd55PharmaRadar360en2026-04-22T19:26:33.000ZBrain Astrocytes Form Far-Reaching Connections in Micehttps://www.pharmaradar360.com/article/2c6c661299ae6ad7PharmaRadar360en2026-04-22T18:58:58.000ZADC Dose Optimization: Applying Model-Informed Strategies in Developmenthttps://www.pharmaradar360.com/article/908062aa88925784PharmaRadar360en2026-04-22T18:49:57.000ZMHC Class II Peptide Binding Prediction: Challenges, AlphaFold 3, and ESM2 Explainedhttps://www.pharmaradar360.com/article/b78ac19017d85bdcPharmaRadar360en2026-04-22T18:38:54.000ZAbbVie's $1.4B North Carolina manufacturing site to finish during Trump's termhttps://www.pharmaradar360.com/article/303993c5bb5d12cePharmaRadar360en2026-04-22T18:35:14.000ZOmaha World-Herald on April 22https://www.pharmaradar360.com/article/3c05d80ee3414a35PharmaRadar360en2026-04-22T18:34:58.000ZSaMD classification: how software as a medical device is categorized by regulatorshttps://www.pharmaradar360.com/article/b8af65973349532bPharmaRadar360en2026-04-22T18:28:29.000ZVictoria Farella makes renewables reliablehttps://www.pharmaradar360.com/article/9ef8cf8445f80046PharmaRadar360en2026-04-22T18:23:00.000ZActionable Alterations and ctDNA Testing May Refine Precision Strategies in Breast and Colorectal Cancershttps://www.pharmaradar360.com/article/c3945c6212646854PharmaRadar360en2026-04-22T18:15:00.000ZCity Limits Subaru and Toyota of Cedar Park go all in on heart health to create a safer communityhttps://www.pharmaradar360.com/article/f793d01d03d6ab01PharmaRadar360en2026-04-22T18:05:39.000ZCellular Mechanisms Behind Diabetes-Derived Vascular Disease Unveiledhttps://www.pharmaradar360.com/article/214f8501c72f700bPharmaRadar360en2026-04-22T18:02:18.000ZMeet Logan: NFL Athlete Thriving with Type 1 Diabeteshttps://www.pharmaradar360.com/article/89e264e1e740f839PharmaRadar360en2026-04-22T17:48:00.000ZThe Pharmacist’s Role in Evaluating 505(b)(2) Drugshttps://www.pharmaradar360.com/article/c0efb9d20ad97250PharmaRadar360en2026-04-22T17:45:48.000ZInmunólogo UC es reconocido por una de las escuelas de medicina más influyentes del mundohttps://www.pharmaradar360.com/article/f68d49b1ffcee633PharmaRadar360en2026-04-22T17:45:38.000ZBusting the myths around the Tobacco and Vapes Billhttps://www.pharmaradar360.com/article/3ba8de003af10f98PharmaRadar360en2026-04-22T17:40:40.000ZAndelyn Partners with S. Korea-Based ENCell to Accelerate Global Delivery of Gene Therapieshttps://www.pharmaradar360.com/article/813029f1ae343f2dPharmaRadar360en2026-04-22T17:40:04.000ZBridgeBio’s oncology spinoff swaps out CEOs as it seeks to accelerate KRAS workhttps://www.pharmaradar360.com/article/236a9dbb86cc9b80PharmaRadar360en2026-04-22T17:36:12.000ZPharmaceutical Executive Daily: Idvynso Receives FDA Approvalhttps://www.pharmaradar360.com/article/9816fd75d51c474bPharmaRadar360en2026-04-22T17:32:19.000ZDisabilities and Women in Ancient Romehttps://www.pharmaradar360.com/article/305c240b86b06a6ePharmaRadar360en2026-04-22T17:15:00.000ZObesity Linked to Increased Risk of Severe Infection, Hospitalization, and Death Across Disease Typeshttps://www.pharmaradar360.com/article/47aec7c93acafa53PharmaRadar360en2026-04-22T17:14:18.000ZCompras y Contratacioneshttps://www.pharmaradar360.com/article/fd2986af7f8203b1PharmaRadar360en2026-04-22T17:08:00.000ZExpert Q&A: Global Supply Chain Pressures and the Future of Drug Availabilityhttps://www.pharmaradar360.com/article/392aa396103488f9PharmaRadar360en2026-04-22T17:06:54.000ZNEWS NEWShttps://www.pharmaradar360.com/article/562bdabf60a98d8aPharmaRadar360en2026-04-22T17:06:47.000ZNavigating The Certification Journey: Why Credentialing Mattershttps://www.pharmaradar360.com/article/1279fecbfbc6975dPharmaRadar360en2026-04-22T16:39:57.000ZPhase 3 NIMBLE Trial: Cemdisiran Proves Efficacy Treating Patients With Generalized Myasthenia Gravishttps://www.pharmaradar360.com/article/8515a9c45e0902f9PharmaRadar360en2026-04-22T16:31:24.000ZSafety concerns continue to plague Roche’s BTK inhibitor in RMShttps://www.pharmaradar360.com/article/e9b00219768cb0d7PharmaRadar360en2026-04-22T16:28:04.000ZMedicare weight loss drug pilot on ice as insurers decline to contributehttps://www.pharmaradar360.com/article/6db718832148b851PharmaRadar360en2026-04-22T16:26:16.000ZCom patrocínio da EMS, “Shrek – O Musical” chega ao Teatro Renault em São Paulohttps://www.pharmaradar360.com/article/ed87aad6c87fa3dfPharmaRadar360en2026-04-22T16:19:48.000ZCash cows, scapegoats — and now global talent: Asian international students want to be seen for who they arehttps://www.pharmaradar360.com/article/5e29cace163d0d3bPharmaRadar360en2026-04-22T16:14:47.000ZPharma-backed petition calls on FDA to reform release of drug rejection lettershttps://www.pharmaradar360.com/article/b9d5124ec2ac4eecPharmaRadar360en2026-04-22T16:07:23.000Z6 UC Irvine professors are elected to American Academy of Arts & Scienceshttps://www.pharmaradar360.com/article/333f9b4c459a7e86PharmaRadar360en2026-04-22T16:02:00.000ZAbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campushttps://www.pharmaradar360.com/article/8a5533821ca7213aPharmaRadar360en2026-04-22T16:00:44.000ZViral Contamination Still a Challenge for CGT Industryhttps://www.pharmaradar360.com/article/c9ce77f63c761b06PharmaRadar360en2026-04-22T16:00:43.000ZAI Wizard Adapts Processes in a Self-Driving Labhttps://www.pharmaradar360.com/article/64b7282b9f6dca5bPharmaRadar360en2026-04-22T16:00:21.000ZMonitoring Mammalian and Microbial Bioprocesses in Real Timehttps://www.pharmaradar360.com/article/0cea022ef14a4a22PharmaRadar360en2026-04-22T16:00:04.000ZOvercoming the VLP Purification Bottleneckhttps://www.pharmaradar360.com/article/b4eb166551e9322ePharmaRadar360en2026-04-22T16:00:00.000ZCMS to Bridge coverage for obesity drugs as BALANCE teetershttps://www.pharmaradar360.com/article/ba84622526aa9ffdPharmaRadar360en2026-04-22T15:51:20.000ZWhat it takes to make elections secure and accessiblehttps://www.pharmaradar360.com/article/f1d9a7e1d2eefaebPharmaRadar360en2026-04-22T15:50:05.000ZDamage to brain’s white matter may play key role in neurodegenerative disease, and could be target for future treatmentshttps://www.pharmaradar360.com/article/c999d34ec1e5fe7fPharmaRadar360en2026-04-22T15:49:50.000ZNew app using AI aims to expand civic engagement in Minnesotahttps://www.pharmaradar360.com/article/8ba9e4aab2e887aaPharmaRadar360en2026-04-22T15:48:19.000ZUMC officially dedicates Nielsen Family Wellness Centerhttps://www.pharmaradar360.com/article/685b4c840e77fe8ePharmaRadar360en2026-04-22T15:40:00.000ZScientific researchers awarded $15 million to study heart valve diseasehttps://www.pharmaradar360.com/article/6c61d2459b3270a6PharmaRadar360en2026-04-22T15:36:28.000ZBTIG Expands its Mortgage and Real Estate Franchisehttps://www.pharmaradar360.com/article/8e5fbb6420daa993PharmaRadar360en2026-04-22T15:28:02.000ZNektar's $325M offering; Maze stock rises; Merck deal rumors; BMS layoffshttps://www.pharmaradar360.com/article/330b22775fbfedd1PharmaRadar360en2026-04-22T15:25:28.000ZSanofi’s new CEO faces a reckoning on immunology-focused R&D strategyhttps://www.pharmaradar360.com/article/aad7ace409c7a79bPharmaRadar360en2026-04-22T15:25:25.000ZAAN 2026: Phase I/II success for rese-cel in gMG signals potential amid competitionhttps://www.pharmaradar360.com/article/b0bd50ea1e209516PharmaRadar360en2026-04-22T15:17:21.000ZAAN 2026: new Vyvgart data show disease control in seronegative gMGhttps://www.pharmaradar360.com/article/867f7c99184efd60PharmaRadar360en2026-04-22T15:17:00.000ZAmazon One Medical launches GLP-1 program integrated with primary carehttps://www.pharmaradar360.com/article/b8f93dcfaa25b691PharmaRadar360en2026-04-22T15:13:57.000ZArtificial intelligence in health technology assessment: Moving from hype to responsible integrationhttps://www.pharmaradar360.com/article/e90588b145802affPharmaRadar360en2026-04-22T15:05:34.000ZUK scientists identify bat coronavirus that can enter human cellshttps://www.pharmaradar360.com/article/40797691082f7352PharmaRadar360en2026-04-22T15:05:01.000ZScientists unlock new route to extreme light intensificationhttps://www.pharmaradar360.com/article/4e3b222024a61e5fPharmaRadar360en2026-04-22T15:04:59.000Zimageshttps://www.pharmaradar360.com/article/dfee63f16a47db18PharmaRadar360en2026-04-22T15:04:59.000ZKinderschutzgruppehttps://www.pharmaradar360.com/article/1cae5714f361207cPharmaRadar360en2026-04-22T15:04:00.000ZKinderschutzgruppehttps://www.pharmaradar360.com/article/1afbc8d741f082fdPharmaRadar360en2026-04-22T15:00:45.000ZCancer waiting times: Latest updates and analysishttps://www.pharmaradar360.com/article/2acc8376838a5ed6PharmaRadar360en2026-04-22T15:00:02.000ZImmunotherapy in locally advanced HNSCC: is there still room for new agents?https://www.pharmaradar360.com/article/569ad62209efeda1PharmaRadar360en2026-04-22T15:00:00.000ZTen Tips for Navigating Pharmacy School Emailshttps://www.pharmaradar360.com/article/2640a48954e50f3cPharmaRadar360en2026-04-22T14:54:00.000ZLilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitorshttps://www.pharmaradar360.com/article/0e38943c632137aaPharmaRadar360en2026-04-22T14:47:46.000ZAAN 2026: frexalimab Phase II OLE data bolsters progressive MS ambitionshttps://www.pharmaradar360.com/article/1c6f4e4f2d8902fbPharmaRadar360en2026-04-22T14:41:53.000ZRigel loses Lilly alliance in pharma industry's latest RIPK exithttps://www.pharmaradar360.com/article/8cf4a90e01962ce2PharmaRadar360en2026-04-22T14:30:00.000ZSPPCP 2026: Lorin Fisher, PhD, Examines Gabapentin’s Expanding Role in Pain Carehttps://www.pharmaradar360.com/article/cc626b0a10547797PharmaRadar360en2026-04-22T14:25:41.000ZDemocracy must be lived, not just declaredhttps://www.pharmaradar360.com/article/e48e329d61820057PharmaRadar360en2026-04-22T14:23:32.000ZMovilidad académica en el Institut Agro Montpellier -Francia-https://www.pharmaradar360.com/article/ab07e0aa67e228dfPharmaRadar360en2026-04-22T14:23:17.000ZMedical Summer School 2026 – University of Rostock (Alemania)https://www.pharmaradar360.com/article/08c79b97142cdb62PharmaRadar360en2026-04-22T14:21:55.000ZLa AEMPS informa del lanzamiento de un programa piloto de la EMA para impulsar el desarrollo de productos sanitarios y productos sanitarios in vitro innovadoreshttps://www.pharmaradar360.com/article/56af6c4f4fda012aPharmaRadar360en2026-04-22T14:21:36.000ZLa AEMPS informa de la detección de productos sanitarios falsos bajo las marcas GEBRO-Mesoceuticals y VANE-Mesoceuticals en el mercado europeohttps://www.pharmaradar360.com/article/5f4347885db4c97fPharmaRadar360en2026-04-22T14:21:00.000ZRFK Jr. continues congressional hearing appearances to talk White House budget planhttps://www.pharmaradar360.com/article/5236f829b3f8df3ePharmaRadar360en2026-04-22T14:18:45.000ZExcellent Achievements: Award for Outstanding Master’s Studenthttps://www.pharmaradar360.com/article/30b9392cd27a6523PharmaRadar360en2026-04-22T14:00:00.000ZStructure of the human P2X3 receptor reveals the basis for subtype-selective inhibition by sivopixanthttps://www.pharmaradar360.com/article/c1f3ae6645438aaePharmaRadar360en2026-04-22T14:00:00.000ZCiliaKB: A comprehensive knowledge base for cilia-associated geneshttps://www.pharmaradar360.com/article/ffcc7235a8b9f221PharmaRadar360en2026-04-22T14:00:00.000ZExpression of Concern: Shellfish dredging pushes a flexible avian top predator out of a marine protected areahttps://www.pharmaradar360.com/article/7074d806170f5cb0PharmaRadar360en2026-04-22T13:59:50.000ZInside the Lab: Advancing Flow Cytometry in Clinical Trials – Q&A with Andre Olsson, PhDhttps://www.pharmaradar360.com/article/71f6d8ce37a6493aPharmaRadar360en2026-04-22T13:58:36.000ZWater, warming and a world at riskhttps://www.pharmaradar360.com/article/677b01eff52634ffPharmaRadar360en2026-04-22T13:58:32.000ZEliohttps://www.pharmaradar360.com/article/6ec74a78bcf76571PharmaRadar360en2026-04-22T13:58:30.000ZFDA Approves Idvynso for Treatment of HIV-1 Infection in Adultshttps://www.pharmaradar360.com/article/89b83731e694bff7PharmaRadar360en2026-04-22T13:57:38.000ZAdrianahttps://www.pharmaradar360.com/article/e225e87428df6163PharmaRadar360en2026-04-22T13:56:44.000ZHenryhttps://www.pharmaradar360.com/article/a98417d34806dfd5PharmaRadar360en2026-04-22T13:55:43.000ZTessa Luciahttps://www.pharmaradar360.com/article/ae88abd1e364f943PharmaRadar360en2026-04-22T13:54:15.000ZManfred Dejan Max Wernerhttps://www.pharmaradar360.com/article/c1181910a2ba4560PharmaRadar360en2026-04-22T13:52:44.000ZMadhawhttps://www.pharmaradar360.com/article/3e98ffb6ef8efcd8PharmaRadar360en2026-04-22T13:51:29.000ZLouis Leonhttps://www.pharmaradar360.com/article/ddbe398047e38916PharmaRadar360en2026-04-22T13:50:39.000ZSam Roberthttps://www.pharmaradar360.com/article/9afcf0d8d4e7fb2ePharmaRadar360en2026-04-22T13:46:36.000ZXeltis gains EU CE mark on positive trial data for vascular access grafthttps://www.pharmaradar360.com/article/5425521acc44efc1PharmaRadar360en2026-04-22T13:45:00.000ZAAN 2026: How Identifying Genetic DEEs Within Existing Trial Data Could Expand the Role of Cannabidiol in Epilepsy Treatmenthttps://www.pharmaradar360.com/article/a0cb61f20dc9cfeaPharmaRadar360en2026-04-22T13:43:14.000ZAvance científico mejora la producción porcina sin antibióticoshttps://www.pharmaradar360.com/article/7db1d5d807d1dcb0PharmaRadar360en2026-04-22T13:42:44.000ZA seminar led to environmental research and dual degreehttps://www.pharmaradar360.com/article/56399a4e27c3124bPharmaRadar360en2026-04-22T13:40:55.000ZReturn of Precious Manuscriptshttps://www.pharmaradar360.com/article/2bf0a4a8c91f1aa8PharmaRadar360en2026-04-22T13:39:03.000ZFDA Expands Teplizumab-Mzwv Approval to Delay Stage 3 Type 1 Diabetes in Children as Young as 1 Yearhttps://www.pharmaradar360.com/article/5e1d254961130747PharmaRadar360en2026-04-22T13:35:28.000ZAdial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trialhttps://www.pharmaradar360.com/article/b6a8de75c02d4884PharmaRadar360en2026-04-22T13:31:52.000ZAmazon One Medical Launches GLP-1 Management Programhttps://www.pharmaradar360.com/article/f153a226aaff4d14PharmaRadar360en2026-04-22T13:31:09.000Z2026 Public Service Awards honor leaders who improve liveshttps://www.pharmaradar360.com/article/815879b5c13c7527PharmaRadar360en2026-04-22T13:30:00.000ZStudent Perspectives on Well-Being in Pharmacy Educationhttps://www.pharmaradar360.com/article/f86a7f6dcae0e218PharmaRadar360en2026-04-22T13:30:00.000ZAAN 2026: What Is PACAP and Why Does It Matter for Migraine? Lundbeck's R&D Chief Explains the Science Behind Bocunebarthttps://www.pharmaradar360.com/article/bb8fee85c7d75896PharmaRadar360en2026-04-22T13:28:16.000ZEvonik Strengthens Biotechnology Capabilities for Drug Substance Manufacturing With New Investment in Slovakiahttps://www.pharmaradar360.com/article/7b417c70e238ad93PharmaRadar360en2026-04-22T13:20:22.000ZCertara Talks – Pivotal Trial Mandatehttps://www.pharmaradar360.com/article/ac1e882ce99c1fe7PharmaRadar360en2026-04-22T13:14:23.000ZToronto academic hospitals deepen climate leadership in second annual sustainability reporthttps://www.pharmaradar360.com/article/57996f9ae59b9cd7PharmaRadar360en2026-04-22T13:14:01.000ZField Safety Notices: 13 to 17 April 2026https://www.pharmaradar360.com/article/60dd5fe53dcb772cPharmaRadar360en2026-04-22T13:05:00.000ZWODC report: greater scope needed for innovative business structures in the legal profession to improve access to justicehttps://www.pharmaradar360.com/article/73cfb6ed7519b849PharmaRadar360en2026-04-22T13:05:00.000ZTwo Central Virginia changemakers triumph in competition to end cardiovascular diseasehttps://www.pharmaradar360.com/article/c4a332443f1bb305PharmaRadar360en2026-04-22T13:02:43.000ZHidden virus in your gut may be linked to colon cancerhttps://www.pharmaradar360.com/article/ff3f674ecd6e9b08PharmaRadar360en2026-04-22T13:02:43.000ZLive Updates From the AACR Annual Meeting 2026: Wednesday, April 22https://www.pharmaradar360.com/article/fa8f8ffc462990f7PharmaRadar360en2026-04-22T13:01:09.000ZScientists find a new way coronaviruses can get into human cellshttps://www.pharmaradar360.com/article/507d591ebdcc778bPharmaRadar360en2026-04-22T12:49:16.000ZRecherche et soin unis face à l’addiction aux opioïdeshttps://www.pharmaradar360.com/article/b0b8e10ef3a83df3PharmaRadar360en2026-04-22T12:48:00.000ZAbbVie to establish NC production base with $1.4B investment, creating 730-plus jobshttps://www.pharmaradar360.com/article/325ce92c258b7bf4PharmaRadar360en2026-04-22T12:44:56.000ZThe Front Office Is Finding Air: One Network’s Early Returns on Operational AIhttps://www.pharmaradar360.com/article/dbf45d8c83a860f8PharmaRadar360en2026-04-22T12:42:38.000ZNucleus RadioPharma Secures $50 Million Financing from OrbiMed to Expand Radiopharmaceutical Manufacturing Capacityhttps://www.pharmaradar360.com/article/4c0ca738b1a4967bPharmaRadar360en2026-04-22T12:40:35.000ZPrograma de Cooperación Latinoamericana y del Caribe en Ciencia, Tecnología e Innovación – PROSUL Pepe Mujicahttps://www.pharmaradar360.com/article/54c8d5ebc17eb2b0PharmaRadar360en2026-04-22T12:36:23.000ZA simple blood test could reveal Alzheimer’s risk years earlyhttps://www.pharmaradar360.com/article/52aaa697e00bca8dPharmaRadar360en2026-04-22T12:28:27.000ZESCMID Global 2026: TherVacB Phase I data supports continued developmenthttps://www.pharmaradar360.com/article/1eb01f9caae5e770PharmaRadar360en2026-04-22T12:10:10.000ZTonic, le magazine des HCL : découvrez le n°205https://www.pharmaradar360.com/article/b693bf60a2354cf5PharmaRadar360en2026-04-22T12:05:56.000ZCough & coldhttps://www.pharmaradar360.com/article/e4f6defa64edf4caPharmaRadar360en2026-04-22T12:05:56.000ZPain managementhttps://www.pharmaradar360.com/article/5666af56f2e14aa6PharmaRadar360en2026-04-22T12:05:56.000ZNeurologyhttps://www.pharmaradar360.com/article/3940739bfa4cc8dbPharmaRadar360en2026-04-22T12:05:56.000ZCardiometabolichttps://www.pharmaradar360.com/article/e32ff86f159f1f12PharmaRadar360en2026-04-22T12:05:56.000ZIntim healthhttps://www.pharmaradar360.com/article/7ef54a56c40fd9bfPharmaRadar360en2026-04-22T12:05:56.000ZGastroenterologyhttps://www.pharmaradar360.com/article/ab23661a4596cb6fPharmaRadar360en2026-04-22T12:05:56.000ZSkin carehttps://www.pharmaradar360.com/article/083fd0132b4d1ec5PharmaRadar360en2026-04-22T12:05:56.000ZAntibiotics and antisepticshttps://www.pharmaradar360.com/article/df9063a5d84849c9PharmaRadar360en2026-04-22T12:05:56.000ZDrugs for Allergyhttps://www.pharmaradar360.com/article/d783a7a1f10bfbd0PharmaRadar360en2026-04-22T12:05:56.000ZПрепарати від застуди та температуриhttps://www.pharmaradar360.com/article/d2006c47b4b1dacbPharmaRadar360en2026-04-22T12:05:56.000ZПрепарати від болю та запаленняhttps://www.pharmaradar360.com/article/a33358460dac0c00PharmaRadar360en2026-04-22T12:05:56.000ZНеврологічні препаратиhttps://www.pharmaradar360.com/article/ac819d19daba5202PharmaRadar360en2026-04-22T12:05:56.000ZКардіометаболічні препаратиhttps://www.pharmaradar360.com/article/cee960841d3c69b1PharmaRadar360en2026-04-22T12:05:56.000ZПрепарати для інтимного здоров'яhttps://www.pharmaradar360.com/article/6332d77eaa049d44PharmaRadar360en2026-04-22T12:05:56.000ZПрепарати для застосування у хірургіїhttps://www.pharmaradar360.com/article/641002ad294e6a51PharmaRadar360en2026-04-22T12:05:56.000ZГастроентерологічні препаратиhttps://www.pharmaradar360.com/article/75b861cdf397b5d8PharmaRadar360en2026-04-22T12:05:56.000ZДерматологічні препаратиhttps://www.pharmaradar360.com/article/d4d1166260db4b5fPharmaRadar360en2026-04-22T12:05:56.000ZАнтибактеріальні препарати та антисептикиhttps://www.pharmaradar360.com/article/80e942b9811775a2PharmaRadar360en2026-04-22T12:05:56.000ZПрепарати при алергіїhttps://www.pharmaradar360.com/article/4e08e0f8b4b7b98bPharmaRadar360en2026-04-22T12:05:56.000ZПрепаратиhttps://www.pharmaradar360.com/article/11036542f29c68f8PharmaRadar360en2026-04-22T12:02:16.000ZMerck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformationhttps://www.pharmaradar360.com/article/fa9b07b20327e7dbPharmaRadar360en2026-04-22T12:01:00.000ZZocdoc partners with Yelp to allow real-time schedulinghttps://www.pharmaradar360.com/article/cd8ba2912dbccca7PharmaRadar360en2026-04-22T12:00:00.000ZManaging QTc Prolongation With CDK4/6 Inhibitor Therapy: A Case-Based Discussionhttps://www.pharmaradar360.com/article/41f54878db2fde5ePharmaRadar360en2026-04-22T12:00:00.000ZFuture Directions for CDK4/6 Inhibitors and the Expanding Role of Pharmacists in Breast Cancer Carehttps://www.pharmaradar360.com/article/c0f24e2f62e5623ePharmaRadar360en2026-04-22T12:00:00.000ZCovid snacking habits and their consequenceshttps://www.pharmaradar360.com/article/612f4d166a1d0429PharmaRadar360en2026-04-22T12:00:00.000ZDécouvrez le magazine Tonic 205https://www.pharmaradar360.com/article/0ef55420eca08bcbPharmaRadar360en2026-04-22T11:59:55.000ZANMAT suspende el certificado de BPF y prohíbe la comercialización de productos médicos de la firma RIPEZZI S.R.L.https://www.pharmaradar360.com/article/7897a72a63b1e913PharmaRadar360en2026-04-22T11:57:43.000ZMSD-backed Ray locks in $125m to back eye drug pipelinehttps://www.pharmaradar360.com/article/052882cebd85a74aPharmaRadar360en2026-04-22T11:53:51.000ZANMAT dispuso la suspensión de habilitaciones de la firma BIOGAMMA S.R.L.https://www.pharmaradar360.com/article/ced855a34d17b08cPharmaRadar360en2026-04-22T11:29:00.000ZCMS delays Part D GLP-1 model amid skepticism from insurershttps://www.pharmaradar360.com/article/8dede68ff806cea3PharmaRadar360en2026-04-22T11:29:00.000ZCMS delays Part D GLP-1 model amid skepticism from insurershttps://www.pharmaradar360.com/article/6451744a86175c52PharmaRadar360en2026-04-22T11:22:26.000ZConCourt judge delivers ‘milestone’ human rights lecturehttps://www.pharmaradar360.com/article/52e7ec0c81df9692PharmaRadar360en2026-04-22T11:11:00.000ZAmneal seizes 'golden era' for biosims with $1.1B Kashiv buyouthttps://www.pharmaradar360.com/article/f9ba39480be916ebPharmaRadar360en2026-04-22T11:05:00.000ZSouth America—the last continent to be settled—was peopled in surprisingly complex wayhttps://www.pharmaradar360.com/article/d15d4ea013830c50PharmaRadar360en2026-04-22T11:03:43.000ZCertara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristathttps://www.pharmaradar360.com/article/338a161945265544PharmaRadar360en2026-04-22T11:00:00.000ZWater, Energy, Circularity: Technologies for a Resilient Futurehttps://www.pharmaradar360.com/article/0e3db441067392afPharmaRadar360en2026-04-22T11:00:00.000ZLabcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®https://www.pharmaradar360.com/article/1193490a45dd9de6PharmaRadar360en2026-04-22T10:57:04.000ZFDA approves MSD’s once-daily HIV combo Idvynsohttps://www.pharmaradar360.com/article/38ef56e080ee998fPharmaRadar360en2026-04-22T10:57:00.000ZSamsung Biologics posts massive revenue growth as labor union rally sets strike in motionhttps://www.pharmaradar360.com/article/2889056a474d95f5PharmaRadar360en2026-04-22T10:46:07.000ZBösartige Weichgewebetumoren besser behandelnhttps://www.pharmaradar360.com/article/1295a48b4a989050PharmaRadar360en2026-04-22T10:30:49.000ZAstraZeneca to seek accelerated approval of Ultomirisin in IgAN on Phase III datahttps://www.pharmaradar360.com/article/1161e31920c03346PharmaRadar360en2026-04-22T10:30:00.000ZFeierliche Eröffnung der Forschungszentren Si-M und BeCAThttps://www.pharmaradar360.com/article/b1d0b38151355c23PharmaRadar360en2026-04-22T10:30:00.000ZBoston Scientific announces results for first quarter 2026https://www.pharmaradar360.com/article/30c652ab65f6c560PharmaRadar360en2026-04-22T10:11:08.000ZAmid global uncertainty, democracy’s future relies on active citizens and bold renewalhttps://www.pharmaradar360.com/article/69436194b459b13aPharmaRadar360en2026-04-22T10:00:22.000ZClass 4 Medicines Defect Notification: Doncaster Pharma Limited, Hiprex 1g tablets, EL(26)A/20https://www.pharmaradar360.com/article/937a558f0fe20b4ePharmaRadar360en2026-04-22T10:00:20.000ZKing’s College Hospital achieves HIMSS INFRAM stage sixhttps://www.pharmaradar360.com/article/e6e9a59ebac1837bPharmaRadar360en2026-04-22T10:00:00.000ZTop Drugs at Risk of Supply Shortages: Reporthttps://www.pharmaradar360.com/article/17a42e4814c13f7aPharmaRadar360en2026-04-22T10:00:00.000ZHow Compounding Has Become a Permanent Bridge for Healthcare Access: Q&A with Dr. Nicole Snowhttps://www.pharmaradar360.com/article/27faad91f228325bPharmaRadar360en2026-04-22T10:00:00.000ZAmneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidancehttps://www.pharmaradar360.com/article/ef0802161ead942aPharmaRadar360en2026-04-22T09:37:00.000ZMerck goes with Google for AI push, striking enterprise partnership worth up to $1Bhttps://www.pharmaradar360.com/article/5c97a678be1ab40bPharmaRadar360en2026-04-22T09:37:00.000ZMerck goes with Google for AI push, striking enterprise partnership worth up to $1Bhttps://www.pharmaradar360.com/article/0a9bff16ddb576edPharmaRadar360en2026-04-22T09:36:40.000Z#Move4Maties: Moving together to help students succeedhttps://www.pharmaradar360.com/article/b594737f2caaf702PharmaRadar360en2026-04-22T09:31:46.000ZBioAegis and Prenosis partner for inflammatory disease therapieshttps://www.pharmaradar360.com/article/28c5b0e206fcc3c7PharmaRadar360en2026-04-22T09:22:03.000ZNy strategi på gång för vården fram till 2040https://www.pharmaradar360.com/article/5e48e6c1e2e1aab4PharmaRadar360en2026-04-22T09:05:24.000ZAntigen‑Stabilized Nanobody Probes Enable On‑Demand, Multicolor Protein Imaginghttps://www.pharmaradar360.com/article/8d45b6453c033a9dPharmaRadar360en2026-04-22T09:00:26.000ZMetagenomic software advance boosts research into microbial diversityhttps://www.pharmaradar360.com/article/907950eddb299414PharmaRadar360en2026-04-22T09:00:02.000ZSpinal Epidural Abscesshttps://www.pharmaradar360.com/article/e4484953a0c62649PharmaRadar360en2026-04-22T09:00:02.000ZHFpEF Explained — Prevalence, New Advances, and How to Diagnosehttps://www.pharmaradar360.com/article/1bfc0d0ca6ea0908PharmaRadar360en2026-04-22T09:00:02.000ZThree Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhagehttps://www.pharmaradar360.com/article/ed5ba0582cf356c9PharmaRadar360en2026-04-22T09:00:02.000ZOral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatientshttps://www.pharmaradar360.com/article/c755adb888e760c7PharmaRadar360en2026-04-22T09:00:02.000ZVibrio vulnificus Necrotizing Soft-Tissue Infection